BRTX
NASDAQ · Biotechnology
Biorestorative Therapies Inc
$1.04
+0.02 (+1.96%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 1.95M | 1.76M | 1.61M |
| Net Income | 368.5K | 288.6K | 237.9K |
| EPS | — | — | — |
| Profit Margin | 18.9% | 16.4% | 14.8% |
| Rev Growth | +23.8% | +14.5% | +14.3% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 3.73M | 3.68M | 4.15M |
| Total Equity | 6.71M | 7.11M | 6.97M |
| D/E Ratio | 0.56 | 0.52 | 0.59 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 506.9K | 503.0K | 417.7K |
| Free Cash Flow | 427.1K | 335.8K | 390.7K |